sarcosine dithiocarbamate has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 1 studies
sarcosine dithiocarbamate: protects against toxicity of alkylating agents
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Valentine, HL | 1 |
| Viquez, OM | 1 |
| Amarnath, K | 1 |
| Amarnath, V | 1 |
| Zyskowski, J | 1 |
| Kassa, EN | 1 |
| Valentine, WM | 1 |
1 other study available for sarcosine dithiocarbamate and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Nitrogen substituent polarity influences dithiocarbamate-mediated lipid oxidation, nerve copper accumulation, and myelin injury.
Topics: Animals; Copper; Demyelinating Diseases; Ditiocarb; Ethylenebis(dithiocarbamates); Lipid Peroxidatio | 2009 |